Citation Impact
Citing Papers
Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
2012
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
2015
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
2008
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
2008
Targeting HER proteins in cancer therapy and the role of the non-target HER3
2007
Hallmarks of Cancer: The Next Generation
2011 Standout
Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
2002
Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma
1992
Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
2010
A view on drug resistance in cancer
2019 StandoutNature
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
1993
Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib
2007
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
2008
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
2011
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Cancer Cell Metabolism: Warburg and Beyond
2008 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response rates
2000
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
2003 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
2014 StandoutNature
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
2008
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
2008
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
2006
Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.
1992
Blinded by the Light: The Growing Complexity of p53
2009 Standout
ErbBs in lung cancer
2008
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study
1994
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Hematopoietic Stem-Cell Transplantation
2006 Standout
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
2017
LKB1; linking cell structure and tumor suppression
2008
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Tumour necrosis factor and cancer
2009
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
1999
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
1993
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
2011
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cancer of the Ovary
2004 Standout
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
1994
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
2015
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
2014
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
1994
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
2000
Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
2007
Metabolic reprogramming and cancer progression
2020 StandoutScience
Cancer Genome Landscapes
2013 StandoutScience
Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer
1992
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
2009
Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma
1991
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
1997
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
2008
Works of B.Y. Yeap being referenced
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
2008
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
1996
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission.
1991
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Inhibitor of apoptosis proteins are regulated by tumour necrosis factor‐α in malignant pleural mesothelioma
2007
Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
1990
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
2007
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
2012
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
1990
Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma
1991
Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.
2010